Seeking Alpha

Prooker

Prooker
Send Message
View as an RSS Feed
View Prooker's Comments BY TICKER:
Latest  |  Highest rated
  • Strong Enrollment In Phase 3 Trial Means Good News For Titan Pharma [View article]
    Ponty - gotta start the clock ticking on those long term gains so you can trade some on the pop for 300a&b. I may take a small position in Titan to hedge my rather heavy CYNAF position at .61.
    Sep 27, 2014. 07:53 PM | Likes Like |Link to Comment
  • A trader's look at Neuralstem [View news story]
    Did i read somewhere recently that CUR had $30 million case on hand?
    May 14, 2014. 06:38 PM | 1 Like Like |Link to Comment
  • Notes From One-On-One Meetings During San Fran Biotech Week - Day 3 [View article]
    Cynapsus is a "sponsor" of some of the Life Sciences Reports they are featured in. $CYNAF. I like this company but have questions about that and why the CSO would leave to become CSO of another micro cap the day after leaving Cynapsus.
    Feb 4, 2014. 08:40 PM | Likes Like |Link to Comment
  • Jason Napodano Positions For 2014: Biotech M&A Growth Trend To Continue [View article]
    Jason what is your take on Dr. Bryson leaving Cynapsus:

    "(Jan. 23, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) is pleased to announces the appointment of Dr. Nathan Bryson to the position of Vice President, Scientific Affairs. Dr. Bryson will replace Mr. Wayne Kreppner who has elected to pursue other opportunities. Dr. Bryson will be responsible for all areas of the Company's research and development activities as well as leading the clinical, regulatory affairs, and manufacturing functions."
    Feb 4, 2014. 08:12 PM | Likes Like |Link to Comment
  • Notes From One-On-One Meetings During San Fran Biotech Week - Day 3 [View article]
    Actually - per this press release he left for another company: (Jan. 23, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) is pleased to announce the appointment of Dr. Nathan Bryson to the position of Vice President, Scientific Affairs. Dr. Bryson will replace Mr. Wayne Kreppner who has elected to pursue other opportunities. Dr. Bryson will be responsible for all areas of the Company's research and development activities as well as leading the clinical, regulatory affairs, and manufacturing functions. Dr. Bryson joins Trimel from Cynapsus Therapeutics where he served as Chief Scientific Officer.
    Feb 4, 2014. 08:09 PM | Likes Like |Link to Comment
COMMENTS STATS
5 Comments
1 Like